Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

by Susana Cedrés, Santiago Ponce-Aix, Jon Zugazagoitia, Irene Sansano, Ana Enguita, Alejandro Navarro-Mendivil, Alex Martinez-Marti, Pablo Martinez, Enriqueta Felip
Published 2015-01-01

Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients

by Ana Callejo, Joan Frigola, Patricia Iranzo, Caterina Carbonell, Nely Diaz, David Marmolejo, Juan David Assaf, Susana Cedrés, Alex Martinez-Marti, Alejandro Navarro, Nuria Pardo, Ramon Amat, Enriqueta Felip
Published 2021-06-01

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients.

by Pablo Martinez, Javier Hernández-Losa, Ma Ángeles Montero, Susana Cedrés, Josep Castellví, Alex Martinez-Marti, Natalia Tallada, Nuria Murtra-Garrell, Alejandro Navarro-Mendivill, Victor Rodriguez-Freixinos, Mercedes Canela, Santiago Ramon y Cajal, Enriqueta Felip
Published 2013-01-01

Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer

by Joan Frigola, Alejandro Navarro, Caterina Carbonell, Ana Callejo, Patricia Iranzo, Susana Cedrés, Alex Martinez‐Marti, Nuria Pardo, Nadia Saoudi‐Gonzalez, Debora Martinez, Jose Jimenez, Irene Sansano, Francesco M. Mancuso, Paolo Nuciforo, Luis M. Montuenga, Montse Sánchez‐Cespedes, Aleix Prat, Ana Vivancos, Enriqueta Felip, Ramon Amat
Published 2021-04-01

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

by João M. Fernandes Neto, Ernest Nadal, Evert Bosdriesz, Salo N. Ooft, Lourdes Farre, Chelsea McLean, Sjoerd Klarenbeek, Anouk Jurgens, Hannes Hagen, Liqin Wang, Enriqueta Felip, Alex Martinez-Marti, August Vidal, Emile Voest, Lodewyk F. A. Wessels, Olaf van Tellingen, Alberto Villanueva, René Bernards
Published 2020-06-01

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

by Raquel Laza‐Briviesca, Alberto Cruz‐Bermúdez, Ernest Nadal, Amelia Insa, María del Rosario García‐Campelo, Gerardo Huidobro, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier De Castro Carpeño, Manuel Cobo, Guillermo López Vivanco, Edel Del Barco, Reyes Bernabé Caro, Nuria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Bartomeu Massuti, Marta Casarrubios, Belén Sierra‐Rodero, Carlos Tarín, Aránzazu García‐Grande, Cara Haymaker, Ignacio I. Wistuba, Atocha Romero, Fernando Franco, Mariano Provencio
Published 2021-07-01